Figure 3.

Subgroup analyses: forest plots of C-reactive protein ≥ 2 mg/L (vs. C-reactive protein < 2 mg/L) and rate of major adverse cardiovascular events. ^Models were adjusted (when appropriate) for age, sex, time since atherosclerotic cardiovascular disease, estimated glomerular filtration rate, albuminuria, comorbidities (diabetes mellitus, hypertension, chronic respiratory disease, cancer, myocardial infarction, angina, heart failure, peripheral vascular disease, stroke/transient ischaemic attack, atrial fibrillation, and rheumatoid diseases), undertaken procedures (coronary artery bypass grafting and percutaneous coronary intervention), and ongoing medications (antiplatelet, non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, beta-blockers, sodium-glucose co-transporter 2 inhibitors, diuretics, calcium channel blockers, digoxin, lipid-lowering treatment (statins, pro-protein convertase subtilisin/kexin type 9 inhibitors, and ezetimibe). CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MACE, major adverse cardiovascular events